News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
328,225 Results
Type
Article (19624)
Company Profile (139)
Press Release (308462)
Section
Business (105192)
Career Advice (869)
Deals (18495)
Drug Delivery (91)
Drug Development (50645)
Employer Resources (79)
FDA (7634)
Job Trends (7717)
News (185513)
Policy (17297)
Tag
Academia (726)
Alliances (27715)
Alzheimer's disease (572)
Approvals (7605)
Artificial intelligence (86)
Bankruptcy (170)
Best Places to Work (5518)
Biosimilars (68)
Biotechnology (63)
Breast cancer (69)
Cancer (650)
Cardiovascular disease (65)
Career advice (704)
Cell therapy (100)
Clinical research (41911)
Collaboration (245)
Compensation (83)
COVID-19 (1074)
C-suite (65)
Data (738)
Diabetes (98)
Diagnostics (1721)
Drug pricing (95)
Earnings (38297)
Employer resources (73)
Events (47748)
Executive appointments (227)
FDA (7930)
Funding (175)
Gene therapy (92)
GLP-1 (496)
Government (1799)
Healthcare (5858)
Infectious disease (1124)
Inflammatory bowel disease (70)
Interviews (114)
IPO (7299)
Job creations (2431)
Job search strategy (645)
Layoffs (253)
Legal (4080)
Lung cancer (101)
Manufacturing (136)
Medical device (1951)
Medtech (1954)
Mergers & acquisitions (11255)
Metabolic disorders (341)
Neuroscience (759)
NextGen Class of 2024 (2347)
Non-profit (902)
Northern California (727)
Obesity (222)
Opinion (174)
Patents (79)
People (32954)
Pharmaceutical (78)
Phase I (13074)
Phase II (17738)
Phase III (14278)
Pipeline (310)
Policy (72)
Postmarket research (1614)
Preclinical (4588)
Radiopharmaceuticals (156)
Rare diseases (153)
Real estate (3164)
Regulatory (12162)
Research institute (816)
Resumes & cover letters (138)
Southern California (667)
Startups (2005)
United States (6615)
Vaccines (215)
Weight loss (189)
Date
Today (78)
Last 7 days (342)
Last 30 days (1460)
Last 365 days (17731)
2024 (17149)
2023 (19637)
2022 (25865)
2021 (26639)
2020 (24871)
2019 (20058)
2018 (15587)
2017 (17253)
2016 (16202)
2015 (18801)
2014 (14787)
2013 (12552)
2012 (13482)
2011 (13817)
2010 (12738)
Location
Africa (406)
Asia (24514)
Australia (3151)
California (1636)
Canada (801)
China (171)
Colorado (70)
Connecticut (64)
Europe (50567)
Florida (237)
Illinois (162)
Indiana (122)
Japan (62)
Maryland (240)
Massachusetts (1376)
Minnesota (95)
New Jersey (639)
New York (468)
North Carolina (367)
Northern California (727)
Ohio (64)
Pennsylvania (388)
South America (604)
Southern California (667)
Texas (223)
Washington State (152)
328,225 Results for "enyo pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
ENYO Pharma Announces a €39 Million Series C Financing and FDA Clearance to Advance Vonafexor in a Phase 2 Clinical Trial for Patients With Alport Syndrome
ENYO Pharma (“ENYO”) announced that it has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 clinical study of Vonafexor, a highly selective FXR agonist, for the treatment of Alport Syndrome.
January 3, 2024
·
3 min read
Editorial
Pharma’s Q3 Was a Rollercoaster Ride. Let’s Do It Again Next Quarter
Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and wonderful world of biopharma.
November 15, 2024
·
3 min read
·
Annalee Armstrong
Business
The Biggest Pharma Share Moves of the Year So Far
Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share price. Other companies have not been so lucky.
November 27, 2024
·
9 min read
·
Annalee Armstrong
MASH
Boston Pharma Carves Out Monthly Treatment Niche in MASH With Strong Phase II Data
Boston Pharma’s once-monthly injection efimosfermin alfa offers a convenient dosing option for MASH patients while also achieving promising rates of fibrosis and MASH improvement, according to a Phase II readout.
November 18, 2024
·
2 min read
·
Tristan Manalac
Rare diseases
Facing a Dearth of Big Pharma Interest, Rare Disease Players Get Creative to Fund R&D
A handful of billion-dollar deals in the rare disease space highlights the uptick in Big Pharma’s investment, but it’s still extremely low compared to the money flowing to more common indications.
November 20, 2024
·
7 min read
·
Heather McKenzie
Opinion
Opinion: A Small Pharma Mindset Can Reshape Big Pharma and Improve Patient Care
An appreciation for practicality, independent thinking and patient care can help disrupt the bureaucracy of Big Pharma.
September 12, 2024
·
3 min read
·
Jill Marie Drury
Layoffs
Athira Pharma to Lay Off 70% of Workforce
Athira Pharma will cut about 49 positions, including two people in the C-suite. The announcement follows the company’s disappointing results for its investigational Alzheimer’s therapy.
September 23, 2024
·
1 min read
·
Angela Gabriel
Business
Astellas Pharma Opens Cambridge Life Sciences Center Featuring Incubator Space
Astellas Pharma’s new life sciences center houses its first U.S.-based SakuLab, an incubator space for external partners, as well as its engineered small molecules unit.
September 6, 2024
·
1 min read
·
Angela Gabriel
Mergers & acquisitions
Broken Deals: 4 Pharma Assets Returned to Biotech This Year
Not all licensing deals are successful. Here,
BioSpace
examines a few noteworthy assets that Big Pharma returned in the last 12 months.
August 27, 2024
·
5 min read
·
Mollie Barnes
Approvals
ARS Pharma Gets FDA Green Light for First Nasal Spray for Severe Allergic Reactions
ARS Pharma’s neffy on Friday became the first FDA-approved nasal spray to address severe allergic reactions, including those that might lead to life-threatening anaphylaxis.
August 12, 2024
·
2 min read
·
Tristan Manalac
1 of 32,823
Next
